X-Ray therapy of Skin Cancer at Critical Facial Sites: Results of a tertiary referral centre.

IF 2.7 3区医学 Q2 DERMATOLOGY

Dermatology Pub Date : 2025-08-26 DOI:10.1159/000548154

Sophie Tschopp, Amélie Ciernik, Reinhard Dummer, Laurence Imhof

{"title":"X-Ray therapy of Skin Cancer at Critical Facial Sites: Results of a tertiary referral centre.","authors":"Sophie Tschopp, Amélie Ciernik, Reinhard Dummer, Laurence Imhof","doi":"10.1159/000548154","DOIUrl":null,"url":null,"abstract":"Background: Therapeutic management of skin cancer (SC) in the \"H-area\" of the face is challenging due to the demands of function, cosmesis, and efficacy.Objective: To evaluate the efficacy and safety of superficial radiotherapy (RT) for skin cancer in the \"H-area\" of the face and to identify predictors of recurrence.Methods: Retrospective analysis of patients with SC in the \"H-area\" of the face treated with superficial RT at the University Hospital of Zurich, Switzerland, between 2010 and 2021. The study included cases of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and in situ SCC (isSCC), lentigo maligna melanoma (LMM), lentigo maligna (LM), and primary cutaneous T/B-cell lymphoma (pcTCL and pcBCL).Results: We identified 550 lesions in 382 patients. Estimated relapse rates at 5 years were lowest for SCC (3.2%), isSCC (1.9%), and BCC (9.7%), while LMM and LM showed estimated relapse rates of 28.9% and 35.0%, respectively. Significant predictive factors for overall recurrence were increased Common Terminology Criteria for Adverse Events (CTCAE) grades with a Hazard Ratio (HR) of 1.9 (1.1-3.4), and the treatment of secondary lesions with a HR of 2.6 (1.4-5.1).Conclusion: RT is a valuable treatment option for malignant skin tumors, especially NMSC, in high-risk areas, including the facial 'H-area', providing favorable results with minimal side effects.","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-22"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548154","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Therapeutic management of skin cancer (SC) in the "H-area" of the face is challenging due to the demands of function, cosmesis, and efficacy.

Objective: To evaluate the efficacy and safety of superficial radiotherapy (RT) for skin cancer in the "H-area" of the face and to identify predictors of recurrence.

Methods: Retrospective analysis of patients with SC in the "H-area" of the face treated with superficial RT at the University Hospital of Zurich, Switzerland, between 2010 and 2021. The study included cases of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and in situ SCC (isSCC), lentigo maligna melanoma (LMM), lentigo maligna (LM), and primary cutaneous T/B-cell lymphoma (pcTCL and pcBCL).

Results: We identified 550 lesions in 382 patients. Estimated relapse rates at 5 years were lowest for SCC (3.2%), isSCC (1.9%), and BCC (9.7%), while LMM and LM showed estimated relapse rates of 28.9% and 35.0%, respectively. Significant predictive factors for overall recurrence were increased Common Terminology Criteria for Adverse Events (CTCAE) grades with a Hazard Ratio (HR) of 1.9 (1.1-3.4), and the treatment of secondary lesions with a HR of 2.6 (1.4-5.1).

Conclusion: RT is a valuable treatment option for malignant skin tumors, especially NMSC, in high-risk areas, including the facial 'H-area', providing favorable results with minimal side effects.

查看原文本刊更多论文

关键面部部位皮肤癌的x射线治疗：三级转诊中心的结果。

背景：面部“h区”皮肤癌（SC）的治疗管理由于功能、美容和疗效的要求而具有挑战性。目的：评价浅表放射治疗面部“h区”皮肤癌的疗效和安全性，并探讨其复发的预测因素。方法：回顾性分析2010年至2021年在瑞士苏黎世大学医院接受浅表RT治疗的面部“h区”SC患者。该研究包括基底细胞癌（BCC）、鳞状细胞癌（SCC）和原位SCC （isSCC）、恶性小痣黑色素瘤（LMM）、恶性小痣瘤（LM）和原发性皮肤T/ b细胞淋巴瘤（pcTCL和pcBCL）。结果：我们在382例患者中发现了550个病变。估计5年复发率最低的是SCC（3.2%）、isSCC（1.9%）和BCC(9.7%)，而LMM和LM的复发率分别为28.9%和35.0%。总体复发的重要预测因素是不良事件通用术语标准（CTCAE）等级的增加，危险比（HR）为1.9(1.1-3.4)，继发性病变的治疗风险比为2.6（1.4-5.1）。结论：在包括面部“h区”在内的高危区域，RT是恶性皮肤肿瘤，特别是NMSC的一种有价值的治疗选择，具有良好的效果和最小的副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology 医学-皮肤病学

CiteScore

6.40

自引率

2.90%

发文量

审稿时长

1 months

期刊介绍： Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.